Deciphera Pharmaceuticals (NASDAQ:DCPH) Given New $30.00 Price Target at Cowen

Deciphera Pharmaceuticals (NASDAQ:DCPHGet Rating) had its price target boosted by analysts at Cowen from $25.00 to $30.00 in a research report issued on Wednesday, The Fly reports. Cowen’s price target would indicate a potential upside of 66.20% from the company’s previous close.

A number of other research analysts have also weighed in on the company. Stifel Nicolaus raised their price objective on Deciphera Pharmaceuticals from $11.00 to $18.00 and gave the company a “hold” rating in a research report on Tuesday, September 27th. Guggenheim upgraded Deciphera Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $22.00 price objective for the company in a research report on Wednesday, January 4th. SVB Leerink raised their price objective on Deciphera Pharmaceuticals from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, January 4th. Barclays raised their price objective on Deciphera Pharmaceuticals from $8.00 to $9.00 and gave the company an “underweight” rating in a research report on Wednesday, January 4th. Finally, Jonestrading upgraded Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Deciphera Pharmaceuticals Stock Performance

Shares of DCPH stock opened at $18.05 on Wednesday. Deciphera Pharmaceuticals has a 52-week low of $6.51 and a 52-week high of $22.76. The firm has a market capitalization of $1.22 billion, a PE ratio of -5.22 and a beta of 0.73. The stock has a fifty day simple moving average of $17.03 and a two-hundred day simple moving average of $16.53.

Deciphera Pharmaceuticals (NASDAQ:DCPHGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.02. Deciphera Pharmaceuticals had a negative return on equity of 63.88% and a negative net margin of 177.53%. The business had revenue of $35.97 million during the quarter, compared to analyst estimates of $33.29 million. On average, sell-side analysts forecast that Deciphera Pharmaceuticals will post -2.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Deciphera Pharmaceuticals news, insider Daniel Lee Flynn sold 2,403 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $21.24, for a total value of $51,039.72. Following the completion of the sale, the insider now owns 43,695 shares of the company’s stock, valued at $928,081.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Deciphera Pharmaceuticals news, insider Daniel Lee Flynn sold 2,403 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $21.24, for a total value of $51,039.72. Following the completion of the sale, the insider now owns 43,695 shares of the company’s stock, valued at $928,081.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Brightstar Associates Llc purchased 1,666,666 shares of the firm’s stock in a transaction dated Tuesday, January 24th. The shares were bought at an average cost of $18.00 per share, with a total value of $29,999,988.00. Following the purchase, the insider now directly owns 19,718,014 shares of the company’s stock, valued at approximately $354,924,252. The disclosure for this purchase can be found here. 4.30% of the stock is owned by insiders.

Institutional Trading of Deciphera Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Deerfield Management Company L.P. Series C raised its stake in Deciphera Pharmaceuticals by 12.0% in the second quarter. Deerfield Management Company L.P. Series C now owns 6,250,964 shares of the company’s stock worth $82,200,000 after buying an additional 670,508 shares in the last quarter. BlackRock Inc. grew its holdings in Deciphera Pharmaceuticals by 27.6% in the first quarter. BlackRock Inc. now owns 4,845,376 shares of the company’s stock worth $44,917,000 after purchasing an additional 1,047,807 shares during the last quarter. Vanguard Group Inc. grew its holdings in Deciphera Pharmaceuticals by 9.2% in the third quarter. Vanguard Group Inc. now owns 4,794,993 shares of the company’s stock worth $88,708,000 after purchasing an additional 402,047 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Deciphera Pharmaceuticals by 356.7% in the second quarter. Goldman Sachs Group Inc. now owns 3,663,819 shares of the company’s stock worth $48,179,000 after purchasing an additional 2,861,642 shares during the last quarter. Finally, Federated Hermes Inc. grew its holdings in Deciphera Pharmaceuticals by 125.5% in the first quarter. Federated Hermes Inc. now owns 1,959,078 shares of the company’s stock worth $18,161,000 after purchasing an additional 1,090,368 shares during the last quarter. Institutional investors own 72.66% of the company’s stock.

Deciphera Pharmaceuticals Company Profile

(Get Rating)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.

Further Reading

The Fly logo

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.